array(1) { [0]=> object(Apache_Solr_Document)#24 (3) { ["_documentBoost":protected]=> bool(false) ["_fields":protected]=> array(6) { ["content_id"]=> array(1) { [0]=> string(13) "DIRECTORY_533" } ["content_title"]=> array(1) { [0]=> string(11) "ADA BERTOLI" } ["description"]=> array(1) { [0]=> string(80952) "Inserire qui il curriculumInsert here the curriculum a:68:{i:0;a:14:{s:9:"citazione";s:391:"Salpini, R., Battisti, A., Piermatteo, L., Carioti, L., Anastasiou, O.E., Gill, U.S., et al. (2020). Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. EMERGING MICROBES & INFECTIONS, 9(1), 928-939.";s:4:"data";s:7:"2020-12";s:2:"id";s:20:"PUBBLICAZIONE_408261";s:6:"handle";s:11:"2108/263821";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/07";s:9:"metadata4";N;s:9:"metadata5";s:242:"Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection";s:9:"metadata6";s:434:"Salpini, R; Battisti, A; Piermatteo, L; Carioti, L; Anastasiou, OE; Gill, US; Di Carlo, D; Colagrossi, L; Duca, L; Bertoli, A; La Rosa, KY; Fabeni, L; Iuvara, A; Malagnino, V; Cerva, C; Lichtner, M; Mastroianni, CM; De Sanctis, GM; Paoloni, M; Marignani, M; Pasquazzi, C; Iapadre, N; Parruti, G; Vecchiet, J; Sarmati, L; Andreoni, M; Angelico, M; Grelli, S; T Kennedy, P; Verheyen, J; Aquaro, S; Silberstein, FC; Perno, CF; Svicher, V";s:9:"metadata7";s:29:"10.1080/22221751.2020.1757998";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:1;a:14:{s:9:"citazione";s:296:"Scutari, R., Piermatteo, L., Ciancio Manuelli, M., Iannetta, M., Salpini, R., Bertoli, A., et al. (2020). Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. LIFE, 10(11), 1-9 [10.3390/life10110302].";s:4:"data";s:10:"2020-11-23";s:2:"id";s:20:"PUBBLICAZIONE_406875";s:6:"handle";s:11:"2108/262629";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/18";s:9:"metadata4";N;s:9:"metadata5";s:147:"Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis";s:9:"metadata6";s:246:"Scutari, R; Piermatteo, L; Ciancio Manuelli, M; Iannetta, M; Salpini, R; Bertoli, A; Alteri, C; Saccomandi, P; Bellocchi, MC; Malagnino, V; Teti, E; Sforza, D; Siragusa, L; Grande, M; Sarmati, L; Svicher, V; Andreoni, M; Ceccherini-Silberstein, F";s:9:"metadata7";s:20:"10.3390/life10110302";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:2;a:14:{s:9:"citazione";s:273:"Scutari, R., Piermatteo, L., Ciancio Manuelli, M., Iannetta, M., Salpini, R., Bertoli, A., et al. (2020). Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. LIFE, 10(11), 1-9.";s:4:"data";s:10:"2020-11-23";s:2:"id";s:20:"PUBBLICAZIONE_403925";s:6:"handle";s:11:"2108/260996";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/17";s:9:"metadata4";N;s:9:"metadata5";s:147:"Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis";s:9:"metadata6";s:246:"Scutari, R; Piermatteo, L; Ciancio Manuelli, M; Iannetta, M; Salpini, R; Bertoli, A; Alteri, C; Saccomandi, P; Bellocchi, MC; Malagnino, V; Teti, E; Sforza, D; Siragusa, L; Grande, M; Sarmati, L; Svicher, V; Andreoni, M; Ceccherini-Silberstein, F";s:9:"metadata7";s:20:"10.3390/life10110302";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:3;a:14:{s:9:"citazione";s:313:"Salpini, R., Piermatteo, L., Battisti, A., Colagrossi, L., Aragri, M., Yu La Rosa, K., et al. (2020). A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. VIRUSES, 12(2), 251 [10.3390/v12020251].";s:4:"data";s:10:"2020-02-23";s:2:"id";s:20:"PUBBLICAZIONE_374369";s:6:"handle";s:11:"2108/233885";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/17";s:9:"metadata4";N;s:9:"metadata5";s:169:"A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro";s:9:"metadata6";s:353:"Salpini, R; Piermatteo, L; Battisti, A; Colagrossi, L; Aragri, M; Yu La Rosa, K; Bertoli, A; Saccomandi, P; Lichtner, M; Marignani, M; Maylin, S; Delaugerre, C; Morisco, F; Coppola, N; Marrone, A; Iapadre, N; Cerva, C; Aquaro, S; Angelico, M; Sarmati, L; Andreoni, M; Verheyen, J; Ceccherini-Silberstein, F; Levrero, M; Perno, CF; Belloni, L; Svicher, V";s:9:"metadata7";s:17:"10.3390/v12020251";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:4;a:14:{s:9:"citazione";s:244:"Armenia, D., Di Carlo, D., Flandre, P., Bouba, Y., Borghi, V., Forbici, F., et al. (2020). HIV MDR is still a relevant issue despite its dramatic drop over the years. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1301-1310 [10.1093/jac/dkz554].";s:4:"data";s:10:"2020-01-24";s:2:"id";s:20:"PUBBLICAZIONE_384209";s:6:"handle";s:11:"2108/242573";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/07";s:9:"metadata4";N;s:9:"metadata5";s:74:"HIV MDR is still a relevant issue despite its dramatic drop over the years";s:9:"metadata6";s:356:"Armenia, D; Di Carlo, D; Flandre, P; Bouba, Y; Borghi, V; Forbici, F; Bertoli, A; Gori, C; Fabeni, L; Gennari, W; Pinnetti, C; Mondi, A; Cicalini, S; Gagliardini, R; Vergori, A; Bellagamba, R; Malagnino, V; Montella, F; Colafigli, M; Latini, A; Marocco, R; Licthner, M; Andreoni, M; Mussini, C; Ceccherini Silberstein, F; Antinori, A; Perno, CF; Santoro, M";s:9:"metadata7";s:18:"10.1093/jac/dkz554";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:5;a:14:{s:9:"citazione";s:364:"Salpini, R., Malagnino, V., Piermatteo, L., Mulas, T., Alkhatib, M., Scutari, R., et al. (2020). Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers. MICROORGANISMS, 8(11), 1-12.";s:4:"data";s:4:"2020";s:2:"id";s:20:"PUBBLICAZIONE_404996";s:6:"handle";s:11:"2108/260990";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore MED/17";s:9:"metadata4";N;s:9:"metadata5";s:237:"Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers";s:9:"metadata6";s:277:"Salpini, R; Malagnino, V; Piermatteo, L; Mulas, T; Alkhatib, M; Scutari, R; Teti, E; Cerva, C; La Rosa, KY; Brugneti, M; Bertoli, A; Rossi, B; Holzmayer, V; Gersch, J; Kuhns, M; Cloherty, G; Ceccherini-Silberstein, F; Perno, C-; Iannetta, M; Andreoni, M; Sarmati, L; Svicher, V";s:9:"metadata7";s:29:"10.3390/microorganisms8111819";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:6;a:14:{s:9:"citazione";s:265:"Armenia, D., Di Carlo, D., Cozzi-Lepri, A., Calcagno, A., Borghi, V., Gori, C., et al. (2019). Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. ANTIVIRAL THERAPY, 24(5), 321-331.";s:4:"data";s:10:"2019-04-12";s:2:"id";s:20:"PUBBLICAZIONE_354587";s:6:"handle";s:11:"2108/217256";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:35:"Settore MED/17 - Malattie Infettive";s:9:"metadata4";N;s:9:"metadata5";s:134:"Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen";s:9:"metadata6";s:349:"Armenia, D; Di Carlo, D; Cozzi-Lepri, A; Calcagno, A; Borghi, V; Gori, C; Bertoli, A; Gennari, W; Bellagamba, R; Castagna, A; Latini, A; Pinnetti, C; Cicalini, S; Saracino, A; Lapadula, G; Rusconi, S; Castelli, F; Di Giambenedetto, S; Andreoni, M; Di Perri, G; Antinori, A; Mussini, C; Ceccherini-Silberstein, F; Monforte, AD; Perno, CF; Santoro, MM";s:9:"metadata7";s:15:"10.3851/IMP3309";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:7;a:14:{s:9:"citazione";s:289:"Bertoli, A., Sorbo, M.C., Aragri, M., Lenci, I., Teti, E., Polilli, E., et al. (2018). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. SCIENTIFIC REPORTS, 8(1), 8988 [10.1038/s41598-018-26862-y].";s:4:"data";s:10:"2018-06-12";s:2:"id";s:20:"PUBBLICAZIONE_331656";s:6:"handle";s:11:"2108/198779";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:140:"Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy";s:9:"metadata6";s:432:"Bertoli, A; Sorbo, MC; Aragri, M; Lenci, I; Teti, E; Polilli, E; Di Maio, VC; Gianserra, L; Biliotti, E; Masetti, C; Magni, CF; Babudieri, S; Nicolini, LA; Milana, M; Cacciatore, P; Sarmati, L; Pellicelli, A; Paolucci, S; Craxì, A; Morisco, F; Palitti, VP; Siciliano, M; Coppola, N; Iapadre, N; Puoti, M; Rizzardini, G; Taliani, G; Pasquazzi, C; Andreoni, M; Parruti, G; Angelico, M; Perno, CF; Cento, V; Ceccherini-Silberstein, F";s:9:"metadata7";s:26:"10.1038/s41598-018-26862-y";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:8;a:14:{s:9:"citazione";s:266:"Di Maio, V.C., Cento, V., Aragri, M., Paolucci, S., Pollicino, T., Coppola, N., et al. (2018). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. JOURNAL OF HEPATOLOGY, 68(3), 597-600.";s:4:"data";s:4:"2018";s:2:"id";s:20:"PUBBLICAZIONE_327259";s:6:"handle";s:11:"2108/194932";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:131:"Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?";s:9:"metadata6";s:234:"Di Maio, VC; Cento, V; Aragri, M; Paolucci, S; Pollicino, T; Coppola, N; Bruzzone, B; Ghisetti, V; Zazzi, M; Brunetto, M; Bertoli, A; Barbaliscia, S; Galli, S; Gennari, W; Baldanti, F; Raimondo, G; Perno, CF; Ceccherini-Silberstein, F";s:9:"metadata7";s:26:"10.1016/j.jhep.2017.09.008";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:9;a:14:{s:9:"citazione";s:233:"Cento, V., Aragri, M., Teti, E., Polilli, E., Bertoli, A., Foroghi, L., et al. (2017). Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkx302].";s:4:"data";s:10:"2017-09-18";s:2:"id";s:20:"PUBBLICAZIONE_320498";s:6:"handle";s:11:"2108/189069";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:35:"Settore MED/17 - Malattie Infettive";s:9:"metadata4";N;s:9:"metadata5";s:85:"Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study";s:9:"metadata6";s:195:"Cento, V; Aragri, M; Teti, E; Polilli, E; Bertoli, A; Foroghi, L; Barbaliscia, S; Di Maio, Vc; Pieri, A; Pace Palitti, V; Sarmati, L; Parruti, G; Andreoni, M; Perno, Cf; Ceccherini-silberstein, F";s:9:"metadata7";s:18:"10.1093/jac/dkx302";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:10;a:14:{s:9:"citazione";s:250:"Fabeni, L., Berno, G., Fokam, J., Bertoli, A., Alteri, C., Gori, C., et al. (2017). Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains. JOURNAL OF CLINICAL MICROBIOLOGY, JCM.00656-17 [10.1128/JCM.00656-17].";s:4:"data";s:10:"2017-07-12";s:2:"id";s:20:"PUBBLICAZIONE_317846";s:6:"handle";s:11:"2108/186616";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:35:"Settore MED/17 - Malattie Infettive";s:9:"metadata4";N;s:9:"metadata5";s:94:"Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains";s:9:"metadata6";s:252:"Fabeni, L; Berno, G; Fokam, J; Bertoli, A; Alteri, C; Gori, C; Forbici, F; Takou, D; Vergori, A; Zaccarelli, M; Maffongelli, G; Borghi, V; Latini, A; Pennica, A; Mastroianni, Cm; Montella, F; Mussini, C; Andreoni, M; Antinori, A; Perno, Cf; Santoro, Mm";s:9:"metadata7";s:20:"10.1128/JCM.00656-17";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:11;a:14:{s:9:"citazione";s:299:"Fabeni, L., Alteri, C., Di Carlo, D., Orchi, N., Carioti, L., Bertoli, A., et al. (2017). Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(10), 2837-2845 [10.1093/jac/dkx231].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_327237";s:6:"handle";s:11:"2108/194918";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:129:"Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14";s:9:"metadata6";s:817:"Fabeni, L; Alteri, C; Di Carlo, D; Orchi, N; Carioti, L; Bertoli, A; Gori, C; Forbici, F; Continenza, F; Maffongelli, G; Pinnetti, C; Vergori, A; Mondi, A; Ammassari, A; Borghi, V; Giuliani, M; De Carli, G; Pittalis, S; Grisetti, S; Pennica, A; Mastroianni, C; Montella, F; Cristaudo, A; Mussini, C; Girardi, E; Andreoni, M; Antinori, A; Ceccherini-Silberstein, F; Perno, C; Santoro, M; Capobianchi, M; Navarra, A; Palummieria, ; Abbate, I; D'Arrigo, R; Fusco, F; Mariano, A; Nicastri, E; Nurra, G; Puro, V; Sampaolesi, A; Sciarrone, M; Scognamiglio, P; Selleri, M; Sias, C; Zaccarelli, M; Di Carlo, A; Giuliani, M; Vullo, V; Falciano, M; Errigo, F; Gattari, P; Spizzichino, L; Schito, S; Sarmati, L; Buonomini, Ar; Cerva, C; Mastroianni, C; Lichtner, M; Mercurio, V; Anzalone, E; Pitorri, A; Caterini, A; Barbacci, S";s:9:"metadata7";s:18:"10.1093/jac/dkx231";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:12;a:14:{s:9:"citazione";s:258:"Soria, A., Alteri, C., Scarlatti, G., Bertoli, A., Tolazzi, M., Balestra, E., et al. (2017). Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report. CLINICAL INFECTIOUS DISEASES, 64(6), 3-15 [10.1093/cid/ciw851].";s:4:"data";s:4:"2017";s:2:"id";s:20:"PUBBLICAZIONE_302359";s:6:"handle";s:11:"2108/173213";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:100:"Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report";s:9:"metadata6";s:197:"Soria, A; Alteri, C; Scarlatti, G; Bertoli, A; Tolazzi, M; Balestra, E; Bellocchi, Mc; Continenza, F; Carioti, L; Biasin, M; Trabattoni, D; Bandera, A; CECCHERINI SILBERSTEIN, F; Perno, Cf; Gori, A";s:9:"metadata7";s:18:"10.1093/cid/ciw851";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:13;a:14:{s:9:"citazione";s:356:"Armenia, D., Di Carlo, D., Calcagno, A., Vendemiati, G., Forbici, F., Bertoli, A., et al. (2016). Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, dkw512 [10.1093/jac/dkw512].";s:4:"data";s:10:"2016-12-20";s:2:"id";s:20:"PUBBLICAZIONE_302355";s:6:"handle";s:11:"2108/173068";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:189:"Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen";s:9:"metadata6";s:306:"Armenia, D; Di Carlo, D; Calcagno, A; Vendemiati, G; Forbici, F; Bertoli, A; Berno, G; Carta, S; Continenza, F; Fedele, V; Bellagamba, R; Cicalini, S; Ammassari, A; Libertone, R; Zaccarelli, M; Ghisetti, V; Andreoni, M; Ceccherini-Silberstein, F; Bonora, S; Di Perri, G; Antinori, A; Perno, Cf; Santoro, MM";s:9:"metadata7";s:18:"10.1093/jac/dkw512";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:14;a:14:{s:9:"citazione";s:343:"Di Maio, V., Cento, V., Di Paolo, D., Aragri, M., De Leonardis, F., Tontodonati, M., et al. (2016). HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(3), 739-750 [10.1093/jac/dkv403].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_253738";s:6:"handle";s:11:"2108/133470";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:166:"HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels";s:9:"metadata6";s:2229:"Di Maio, V; Cento, V; Di Paolo, D; Aragri, M; De Leonardis, F; Tontodonati, M; Micheli, V; Bellocchi, M; Antonucci, F; Bertoli, A; Lenci, I; Milana, M; Gianserra, L; Melis, M; Di Biagio, A; Sarrecchia, C; Sarmati, L; Landonio, S; Francioso, S; Lambiase, L; Nicolini, L; Marenco, S; Nosotti, L; Giannelli, V; Siciliano, M; Romagnoli, D; Pellicelli, A; Vecchiet, J; Magni, C; Babudieri, S; Mura, M; Taliani, G; Mastroianni, C; Vespasiani Gentilucci, U; Romano, M; Morisco, F; Gasbarrini, A; Vullo, V; Bruno, S; Baiguera, C; Pasquazzi, C; Tisone, G; Picciotto, A; Andreoni, M; Parruti, G; Rizzardini, G; Angelico, M; Perno, CF; Ceccherini Silberstein, F; Mariani, R; Paoloni, M; Iapadre, N; Grimaldi, A; Menzaghi, B; Quirino, T; Vecchiet, J; Bruzzone, B; De Maria, A; Di Biagio, A; Marenco, S; Nicolini, L; Picciotto, A; Viscoli, C; Casinelli, K; Monache, M; Lichtner, M; Mastroianni, C; Aghemo, A; Bruno, S; Cerrone, M; Colombo, M; Monforte, A; Danieli, E; Donato, F; Gubertini, G; Landonio, S; Magni, C; Mancon, A; Micheli, V; Monico, S; Niero, F; Puoti, M; Rizzardini, G; Russo, M; Alfieri, R; Gnocchi, M; Orro, A; Milanesi, L; Baldelli, E; Bertolotti, M; Borghi, V; Mussini, C; Romagnoli, D; Brancaccio, G; Caporaso, N; Gaeta, G; Lembo, V; Morisco, F; Calvaruso, V; Craxì, A; Di Marco, V; Mazzola, A; Petta, S; D'Amico, E; Cacciatore, P; Consorte, A; Palitti, V; Parruti, G; Pieri, A; Polilli, E; Tontodonati, M; Andreoni, M; Angelico, M; Antenucci, F; Antonucci, F; Aragri, M; Armenia, D; Baiocchi, L; Bellocchi, M; Biliotti, E; Biolato, M; Carioti, L; Cento, V; Cerasari, G; Cerva, C; Ciotti, M; D'Ambrosio, C; D'Ettorre, G; De Leonardis, F; De Sanctis, A; Di Maio, V; Di Paolo, D; Francioso, S; Furlan, C; Gallo, P; Gasbarrini, A; Giannelli, V; Gianserra, L; Grieco, A; Grieco, S; Lambiase, L; Lattanzi, B; Lenci, I; Malagnino, V; Manuelli, M; Merli, M; Miglioresi, L; Milana, M; Nosotti, L; Palazzo, D; Pasquazzi, C; Pellicelli, A; Romano, M; Santopaolo, F; Santoro, M; Sarmati, L; Sarrecchia, C; Sforza, D; Siciliano, M; Sorbo, M; Spaziante, M; Svicher, V; Taliani, G; Teti, E; Tisone, G; Vespasiani Gentilucci, U; Vullo, V; Mangia, A; Babudieri, S; Maida, I; Melis, M; Mura, M; Falconi, L; Di Giammartino, D; Tarquini, P";s:9:"metadata7";s:18:"10.1093/jac/dkv403";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:15;a:14:{s:9:"citazione";s:277:"Maffongelli, G., Alterib, C., Gentilotti, E., Bertoli, A., Ricciardi, A., Malagnino, V., et al. (2016). Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. AIDS [10.1097/QAD.0000000000000977].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_253986";s:6:"handle";s:11:"2108/133866";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:135:"Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy";s:9:"metadata6";s:151:"Maffongelli, G; Alterib, C; Gentilotti, E; Bertoli, A; Ricciardi, A; Malagnino, V; Svicher, V; Santoro, Mm; Dori, L; Perno, Cf; Andreoni, M; Sarmati, L";s:9:"metadata7";s:28:"10.1097/QAD.0000000000000977";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:16;a:14:{s:9:"citazione";s:291:"Palma, P., Zangari, P., Alteri, C., Tchidjou, H.k., Manno, E.c., Liuzzi, G., et al. (2016). Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child. BMC INFECTIOUS DISEASES, 16(1), 742 [10.1186/s12879-016-2092-z].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_300387";s:6:"handle";s:11:"2108/171267";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:51:"Settore MED/38 - Pediatria Generale e Specialistica";s:9:"metadata4";N;s:9:"metadata5";s:133:"Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child";s:9:"metadata6";s:113:"Palma, P; Zangari, P; Alteri, C; Tchidjou, Hk; Manno, Ec; Liuzzi, G; Perno, Cf; Rossi, P; Bertoli, A; Bernardi, S";s:9:"metadata7";s:25:"10.1186/s12879-016-2092-z";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:17;a:14:{s:9:"citazione";s:335:"Zaccarelli, M., Santoro, M.m., Armenia, D., Borghi, V., Gennari, W., Gori, C., et al. (2016). Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. JOURNAL OF CLINICAL VIROLOGY, 82, 94-100 [10.1016/j.jcv.2016.07.007].";s:4:"data";s:4:"2016";s:2:"id";s:20:"PUBBLICAZIONE_290346";s:6:"handle";s:11:"2108/162527";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:170:"Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA";s:9:"metadata6";s:240:"Zaccarelli, M; Santoro, Mm; Armenia, D; Borghi, V; Gennari, W; Gori, C; Forbici, F; Bertoli, A; Fabeni, L; Giannetti, A; Cicalini, S; Bellagamba, R; Andreoni, M; Mastroianni, Cm; Mussini, C; Ceccherini-Silberstein, F; Perno, CF; Antinori, A";s:9:"metadata7";s:25:"10.1016/j.jcv.2016.07.007";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:18;a:14:{s:9:"citazione";s:296:"Surdo, M., Bertoli, A., Colucci, G., Sarmati, L., Andreoni, M., Perno, C.F., et al. (2015). Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 54(2), e57-e59 [10.1515/cclm-2015-0647].";s:4:"data";s:10:"2015-09-24";s:2:"id";s:20:"PUBBLICAZIONE_253958";s:6:"handle";s:11:"2108/133646";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:118:"Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0";s:9:"metadata6";s:106:"Surdo, M; Bertoli, A; Colucci, G; Sarmati, L; Andreoni, M; Perno, CF; Ceccherini Silberstein, F; Ciotti, M";s:9:"metadata7";s:22:"10.1515/cclm-2015-0647";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:19;a:14:{s:9:"citazione";s:277:"Fabeni, L., Berno, G., Svicher, V., Ceccherini-Silberstein, F., Gori, C., Bertoli, A., et al. (2015). Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia. JOURNAL OF CLINICAL MICROBIOLOGY, 53(9), 2935-2941 [10.1128/JCM.00893-15].";s:4:"data";s:7:"2015-07";s:2:"id";s:20:"PUBBLICAZIONE_253960";s:6:"handle";s:11:"2108/133648";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:99:"Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia";s:9:"metadata6";s:223:"Fabeni, L; Berno, G; Svicher, V; Ceccherini-Silberstein, F; Gori, C; Bertoli, A; Mussini, C; Lichtner, M; Zaccarelli, M; Ammassari, A; Pinnetti, C; Cicalini, S; Mastroianni, C; Andreoni, M; Antinori, A; Perno, C; Santoro, M";s:9:"metadata7";s:20:"10.1128/JCM.00893-15";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:20;a:14:{s:9:"citazione";s:330:"Cento, V., Tontodonati, M., Di Maio, V.c., Bellocchi, M.c., Valenti, F., Manunta, A., et al. (2015). Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. DIGESTIVE AND LIVER DISEASE, 47(3), 233-241 [10.1016/j.dld.2014.12.004].";s:4:"data";s:7:"2015-05";s:2:"id";s:20:"PUBBLICAZIONE_231212";s:6:"handle";s:11:"2108/113131";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:155:"Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice";s:9:"metadata6";s:279:"Cento, V; Tontodonati, M; Di Maio, Vc; Bellocchi, Mc; Valenti, F; Manunta, A; Fortuna, S; Armenia, D; Carioti, L; Antonucci, Fp; Bertoli, A; Trave, F; Cacciatore, P; Angelico, M; Navarra, P; Neumann, Au; Vecchiet, J; Parruti, G; Babudieri, S; Perno, Cf; Ceccherini-Silberstein, F";s:9:"metadata7";s:25:"10.1016/j.dld.2014.12.004";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:21;a:14:{s:9:"citazione";s:291:"Fabeni, L., Alteri, C., Orchi, N., Gori, C., Bertoli, A., Forbici, F., et al. (2015). Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy. PLOS ONE, 10(8), e0135325 [10.1371/journal.pone.0135325].";s:4:"data";s:4:"2015";s:2:"id";s:20:"PUBBLICAZIONE_254005";s:6:"handle";s:11:"2108/133892";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:146:"Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy";s:9:"metadata6";s:258:"Fabeni, L; Alteri, C; Orchi, N; Gori, C; Bertoli, A; Forbici, F; Montella, F; Pennica, A; De Carli, G; Giuliani, M; Continenza, F; Pinnetti, C; Nicastri, E; Ceccherini-Silberstein, F; Mastroianni, C; Girardi, E; Andreoni, M; Antinori, A; Santoro, M; Perno, C";s:9:"metadata7";s:28:"10.1371/journal.pone.0135325";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:22;a:14:{s:9:"citazione";s:304:"Mirabelli, C., Surdo, M., Van Hemert, F., Lian, Z., Salpini, R., Cento, V., et al. (2014). Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. JOURNAL OF INFECTION [10.1016/j.jinf.2014.10.015].";s:4:"data";s:10:"2014-11-06";s:2:"id";s:20:"PUBBLICAZIONE_214490";s:6:"handle";s:11:"2108/113050";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:161:"Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection";s:9:"metadata6";s:401:"Mirabelli, C; Surdo, M; Van Hemert, F; Lian, Z; Salpini, R; Cento, V; Cortese, M; Aragri, M; Pollicita, M; Alteri, C; Bertoli, A; Berkhout, B; Micheli, V; Gubertini, G; Santoro, M; Romano, S; Visca, M; Bernassola, M; Longo, R; De Sanctis, G; Trimoulet, P; Fleury, H; Marino, N; Mazzotta, F; Cappiello, G; Spanò, A; Sarrecchia, C; Zhang, J; Andreoni, M; Angelico, M; Verheyen, J; Perno, C; Svicher, V";s:9:"metadata7";s:26:"10.1016/j.jinf.2014.10.015";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:23;a:14:{s:9:"citazione";s:282:"Armenia, D., Soulie, C., Di Carlo, D., Fabeni, L., Gori, C., Forbici, F., et al. (2014). A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. PLOS ONE, 9(8) [10.1371/journal.pone.0105853].";s:4:"data";s:7:"2014-08";s:2:"id";s:20:"PUBBLICAZIONE_213108";s:6:"handle";s:11:"2108/100778";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:35:"Settore MED/17 - Malattie Infettive";s:9:"metadata4";N;s:9:"metadata5";s:146:"A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.";s:9:"metadata6";s:268:"Armenia, D; Soulie, C; Di Carlo, D; Fabeni, L; Gori, C; Forbici, F; Svicher, V; Bertoli, A; Sarmati, L; Giuliani, M; Latini, A; Boumis, E; Zaccarelli, M; Bellagamba, R; Andreoni, M; Marcelin, AG; Calvez, V; Antinori A; Ceccherini-Silberstein, F; Perno, CF; Santoro, MM";s:9:"metadata7";s:28:"10.1371/journal.pone.0105853";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:24;a:14:{s:9:"citazione";s:266:"Santoro, M., Fabeni, L., Armenia, D., Alteri, C., Di Pinto, D., Forbici, F., et al. (2014). Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. CLINICAL INFECTIOUS DISEASES, 58(8), 1156-1164 [10.1093/cid/ciu020].";s:4:"data";s:7:"2014-04";s:2:"id";s:20:"PUBBLICAZIONE_185030";s:6:"handle";s:10:"2108/89703";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:104:"Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels";s:9:"metadata6";s:312:"Santoro, M; Fabeni, L; Armenia, D; Alteri, C; Di Pinto, D; Forbici, F; Bertoli, A; Di Carlo, D; Gori, C; Carta, S; Fedele, V; D'Arrigo, R; Berno, G; Ammassari, A; Pinnetti, C; Nicastri, E; Latini, A; Tommasi, C; Boumis, E; Petrosillo, N; D'Offizi, G; Andreoni, M; Ceccherini Silberstein, F; Antinori, A; Perno, C";s:9:"metadata7";s:18:"10.1093/cid/ciu020";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:25;a:14:{s:9:"citazione";s:275:"Svicher, V., Alteri, C., Montano, M., Nori, A., D'Arrigo, R., Andreoni, M., et al. (2014). Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. INFECTION, 42(1), 61-71 [10.1007/s15010-013-0510-3].";s:4:"data";s:7:"2014-02";s:2:"id";s:20:"PUBBLICAZIONE_185024";s:6:"handle";s:10:"2108/89706";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:130:"Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group";s:9:"metadata6";s:898:"Svicher, V; Alteri, C; Montano, M; Nori, A; D'Arrigo, R; Andreoni, M; Angarano, G; Antinori, A; Antonelli, G; Allice, T; Bagnarelli, P; Baldanti, F; Bertoli, A; Borderi, M; Boeri, E; Bon, I; Bruzzone, B; Barresi, R; Calderisi, S; Callegaro, A; Capobianchi, M; Gargiulo, F; Castelli, F; Cauda, R; Ceccherini-Silberstein, F; Clementi, M; Chirianni, A; Colafigli, M; D'Arminio Monforte, A; De Luca, A; Di Biagio, A; Di Nicuolo, G; Di Perri, G; Di Santo, F; Fadda, G; Galli, M; Gennari, W; Ghisetti, V; Costantini, A; Gori, A; Gulminetti, R; Leoncini, F; Maffongelli, G; Maggiolo, F; Maserati, R; Mazzotta, F; Meini, G; Micheli, V; Monno, L; Mussini, C; Nozza, S; Paolucci, S; Palù, G; Parisi, S; Parruti, G; Pignataro, A; Quirino, T; Re, M; Rizzardini, G; Sanguinetti, M; Santangelo, R; Scaggiante, R; Sterrantino, G; Turriziani, O; Vatteroni, M; Viscoli, C; Vullo, V; Zazzi, M; Lazzarin, A; Perno, C";s:9:"metadata7";s:25:"10.1007/s15010-013-0510-3";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:26;a:14:{s:9:"citazione";s:275:"Cento, V., Van Hemert, F., Neumann Fraune, M., Mirabelli, C., Di Maio, V., Salpini, R., et al. (2013). Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. JOURNAL OF INFECTION, 67(4), 303-312 [10.1016/j.jinf.2013.05.008].";s:4:"data";s:10:"2013-06-22";s:2:"id";s:20:"PUBBLICAZIONE_158902";s:6:"handle";s:10:"2108/75669";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:104:"Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen";s:9:"metadata6";s:321:"Cento, V; Van Hemert, F; Neumann Fraune, M; Mirabelli, C; Di Maio, V; Salpini, R; Bertoli, A; Micheli, V; Gubertini, G; Romano, S; Visca, M; De Sanctis, G; Berkhout, B; Marino, N; Mazzotta, F; Cappiello, G; Spanò, A; Sarrecchia, C; CECCHERINI SILBERSTEIN, F; Andreoni, M; Angelico, M; Verheyen, J; Perno, Cf; Svicher, V";s:9:"metadata7";s:26:"10.1016/j.jinf.2013.05.008";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:27;a:14:{s:9:"citazione";s:350:"Alteri, C., Artese, A., Beheydt, G., Santoro, M., Costa, G., Parrotta, L., et al. (2013). Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(10), 2205-2209 [10.1093/jac/dkt173].";s:4:"data";s:7:"2013-05";s:2:"id";s:20:"PUBBLICAZIONE_254428";s:6:"handle";s:11:"2108/134050";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:180:"Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen";s:9:"metadata6";s:230:"Alteri, C; Artese, A; Beheydt, G; Santoro, M; Costa, G; Parrotta, L; Bertoli, A; Gori, C; Orchi, N; Girardi, E; Antinori, A; Alcaro, S; d'Arminio Monforte, A; Theys, K; Vandamme, A; CECCHERINI SILBERSTEIN, F; Svicher, V; Perno, Cf";s:9:"metadata7";s:18:"10.1093/jac/dkt173";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:28;a:14:{s:9:"citazione";s:256:"Cento, V., Mirabelli, C., Dimonte, S., Salpini, R., Han, Y., Trimoulet, P., et al. (2012). Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution. JOURNAL OF GENERAL VIROLOGY [10.1099/vir.0.046524-0].";s:4:"data";s:10:"2012-10-10";s:2:"id";s:20:"PUBBLICAZIONE_148589";s:6:"handle";s:10:"2108/71491";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:110:"Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution";s:9:"metadata6";s:281:"Cento, V; Mirabelli, C; Dimonte, S; Salpini, R; Han, Y; Trimoulet, P; Bertoli, A; Micheli, V; Gubertini, G; Cappiello, G; Spano, A; Longo, R; Bernassola, M; Mazzotta, F; De Sanctis, GM; Zhang, XX; Verheyen, J; D'Arminio Monforte, A; Ceccherini-Silberstein, F; Perno, CF; Svicher, V";s:9:"metadata7";s:22:"10.1099/vir.0.046524-0";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:29;a:14:{s:9:"citazione";s:174:"Ciccozzi, M., Santoro, M., Giovanetti, M., Andrissi, L., Bertoli, A., & Ciotti, M. (2012). HIV-1 non-B subtypes in Italy: a growing trend. NEW MICROBIOLOGICA, 35(4), 377-386.";s:4:"data";s:7:"2012-10";s:2:"id";s:20:"PUBBLICAZIONE_247882";s:6:"handle";s:11:"2108/129016";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:46:"HIV-1 non-B subtypes in Italy: a growing trend";s:9:"metadata6";s:74:"Ciccozzi, M; Santoro, M; Giovanetti, M; Andrissi, L; Bertoli, A; Ciotti, M";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:30;a:14:{s:9:"citazione";s:281:"Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2012). The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. CLINICAL MICROBIOLOGY AND INFECTION, 18(8) [10.1111/j.1469-0691.2012.03905.x].";s:4:"data";s:10:"2012-08-03";s:2:"id";s:20:"PUBBLICAZIONE_139056";s:6:"handle";s:10:"2108/68004";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:112:"The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients";s:9:"metadata6";s:235:"Santoro, M; Armenia, D; Fabeni, L; Santoro, M; Gori, C; Forbici, F; Svicher, V; Bertoli, A; Dori, L; Surdo, M; Balestra, E; Palamara, G; Girardi, E; Angarano, G; Andreoni, M; Narciso, P; Antinori, A; Ceccherini Silberstein, F; Perno, C";s:9:"metadata7";s:32:"10.1111/j.1469-0691.2012.03905.x";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:31;a:14:{s:9:"citazione";s:269:"Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Van Hemert, F., Chen, M., et al. (2012). Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. ANTIVIRAL RESEARCH, 93(1), 86-93 [10.1016/j.antiviral.2011.10.022].";s:4:"data";s:7:"2012-01";s:2:"id";s:20:"PUBBLICAZIONE_162612";s:6:"handle";s:10:"2108/77109";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:100:"Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.";s:9:"metadata6";s:302:"Svicher, V; Cento, V; Bernassola, M; Neumann-Fraune, M; Van Hemert, F; Chen, M; Salpini, R; Liu, C; Longo, R; Visca, M; Romano, S; Micheli, V; Bertoli, A; Gori, C; Ceccherini-Silberstein, F; Sarrecchia, C; Andreoni, M; Angelico, M; Ursitti, A; Spanò, A; Zhang, JM; Verheyen, J; Cappiello, G; Perno, CF";s:9:"metadata7";s:31:"10.1016/j.antiviral.2011.10.022";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:32;a:14:{s:9:"citazione";s:267:"Cento, V., Mirabelli, C., Salpini, R., Dimonte, S., Artese, A., Costa, G., et al. (2012). HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLOS ONE, 7(7), e39652-e39652 [10.1371/journal.pone.0039652].";s:4:"data";s:4:"2012";s:2:"id";s:20:"PUBBLICAZIONE_144484";s:6:"handle";s:10:"2108/69748";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:114:"HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors";s:9:"metadata6";s:231:"Cento, V; Mirabelli, C; Salpini, R; Dimonte, S; Artese, A; Costa, G; Mercurio, F; Svicher, V; Parrotta, L; Bertoli, A; Ciotti, M; Di Paolo, D; Sarrecchia, C; Andreoni, M; Alcaro, S; Angelico, M; Perno, Cf; CECCHERINI SILBERSTEIN, F";s:9:"metadata7";s:28:"10.1371/journal.pone.0039652";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:33;a:14:{s:9:"citazione";s:288:"Cento, V., Van Hemert, F., Di Maio, V., Salpini, R., Mirabelli, C., Bertoli, A., et al. (2012). Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen. In JOURNAL OF HEPATOLOGY (pp.S198-S199).";s:4:"data";s:4:"2012";s:2:"id";s:20:"PUBBLICAZIONE_138902";s:6:"handle";s:10:"2108/67927";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:150:"Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen";s:9:"metadata6";s:282:"Cento, V; Van Hemert, F; Di Maio, V; Salpini, R; Mirabelli, C; Bertoli, A; Gori, C; Micheli, V; Gubertini, G; Longo, R; Romano, S; Visca, M; De Sanctis, G; Marino, N; Mazzotta, F; Cappiello, G; Sarrecchia, C; Ceccherini-Silberstein, F; Andreoni, M; Angelico, M; Perno, C; Svicher, V";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:34;a:14:{s:9:"citazione";s:300:"Santoro, M.M., Alteri, C., Ronga, L., Flandre, P., Fabeni, L., Mercurio, F., et al. (2012). Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 28(10), 1285-1293 [10.1089/aid.2011.0142].";s:4:"data";s:4:"2012";s:2:"id";s:20:"PUBBLICAZIONE_148048";s:6:"handle";s:10:"2108/71248";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:126:"Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy";s:9:"metadata6";s:285:"Santoro, MM; Alteri, C; Ronga, L; Flandre, P; Fabeni, L; Mercurio, F; D'Arrigo, R; Gori, C; Palamara, G; Bertoli, A; Forbici, F; Salpini, R; Boumis, E; Tozzi, V; Visco-Comandini, U; Zaccarelli, M; Van Houtte, M; Pattery, T; Narciso, P; Antinori, A; Ceccherini-Silberstein, F; Perno, CF";s:9:"metadata7";s:21:"10.1089/aid.2011.0142";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:35;a:14:{s:9:"citazione";s:242:"Svicher, V., Alteri, C., Montano, M., D'Arrigo, R., Andreoni, M., Angarano, G., et al. (2012). Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group. NEW MICROBIOLOGICA, 35(1), 17-25.";s:4:"data";s:4:"2012";s:2:"id";s:20:"PUBBLICAZIONE_138911";s:6:"handle";s:10:"2108/67952";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:112:"Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group";s:9:"metadata6";s:930:"Svicher, V; Alteri, C; Montano, M; D'Arrigo, R; Andreoni, M; Angarano, G; Antinori, A; Antonelli, G; Allice, T; Bagnarelli, P; Baldanti, F; Bertoli, A; Borderi, M; Boeri, E; Bon, I; Bruzzone, B; Callegaro, A; Capobianchi, M; Carosi, G; Cauda, R; Ceccherini-Silberstein, F; Clementi, M; Chirianni, A; Colafigli, M; Monforte, A; De Luca, A; Di Biagio, A; Di Nicuolo, G; Di Perri, G; Di Pietro, M; Di Santo, F; Fabeni, L; Fadda, G; Galli, M; Gennari, W; Ghisetti, V; Giacometti, A; Gori, C; Gori, A; Gulminetti, R; Leoncini, F; Maffongelli, G; Maggiolo, F; Manca, G; Gargiulo, F; Martinelli, C; Maserati, R; Mazzotta, F; Meini, G; Micheli, V; Monno, L; Mussini, C; Narciso, P; Nozza, S; Paolucci, S; Palu, G; Parisi, S; Parruti, G; Pignataro, A; Pollicita, M; Quirino, T; Re, M; Rizzardini, G; Santangelo, R; Scaggiante, R; Sterrantino, G; Turriziani, O; Vatteroni, M; Vecchi, L; Viscoli, C; Vullo, V; Zazzi, M; Lazzarin, A; Perno, C";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:36;a:14:{s:9:"citazione";s:372:"Svicher, V., Mirabelli, C., Cento, V., Salpini, R., Di Maio, V., Bertoli, A., et al. (2012). Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo. Paper presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Barcelona, SPAIN [10.1016/S0168-8278(12)60500-5].";s:4:"data";s:4:"2012";s:2:"id";s:20:"PUBBLICAZIONE_138904";s:6:"handle";s:10:"2108/67964";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:126:"Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo";s:9:"metadata6";s:305:"Svicher, V; Mirabelli, C; Cento, V; Salpini, R; Di Maio, V; Bertoli, A; Alteri, C; Pollicita, M; Gori, C; Micheli, V; Salso, A; Gubertini, G; Trimoulet, P; Fleury, H; Vecchiet, J; Iapadre, N; Barlattani, A; Mari, T; Pasquazzi, C; Sarrechia, C; Ceccherini-Silberstein, F; Andreoni, M; Angelico, M; Perno, C";s:9:"metadata7";s:29:"10.1016/S0168-8278(12)60500-5";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:37;a:14:{s:9:"citazione";s:345:"Alcaro, S., Alteri, C., Artese, A., Ceccherini-Silberstein, F., Costa, G., Ortuso, F., et al. (2011). Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. CHEMMEDCHEM, 6(12), 2203-2213 [10.1002/cmdc.201100362].";s:4:"data";s:10:"2011-12-09";s:2:"id";s:19:"PUBBLICAZIONE_81007";s:6:"handle";s:10:"2108/50407";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:186:"Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine";s:9:"metadata6";s:223:"Alcaro, S; Alteri, C; Artese, A; Ceccherini-Silberstein, F; Costa, G; Ortuso, F; Bertoli, A; Forbici, F; Santoro, M; Parrotta, L; Flandre, P; Masquelier, B; Descamps, D; Calvez, V; Marcelin, A; Perno, C; Sing, T; Svicher, V";s:9:"metadata7";s:22:"10.1002/cmdc.201100362";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:38;a:14:{s:9:"citazione";s:329:"Ceccarelli, L., Salpini, R., Sarmati, L., Svicher, V., Bertoli, A., Sordillo, P., et al. (2011). Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. JOURNAL OF INFECTION, 65(2) [10.1016/j.jinf.2011.11.021].";s:4:"data";s:10:"2011-11-23";s:2:"id";s:19:"PUBBLICAZIONE_85114";s:6:"handle";s:10:"2108/51801";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:173:"Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy";s:9:"metadata6";s:126:"Ceccarelli, L; Salpini, R; Sarmati, L; Svicher, V; Bertoli, A; Sordillo, P; Ricciardi, A; Perno, C; Andreoni, M; Sarrecchia, C";s:9:"metadata7";s:26:"10.1016/j.jinf.2011.11.021";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:39;a:14:{s:9:"citazione";s:265:"Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Hemert, F., Chen, M., et al. (2011). Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. ANTIVIRAL RESEARCH, 93(1), 86-93 [10.1016/j.antiviral.2011.10.022].";s:4:"data";s:10:"2011-11-09";s:2:"id";s:19:"PUBBLICAZIONE_81005";s:6:"handle";s:10:"2108/50411";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:99:"Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection";s:9:"metadata6";s:297:"Svicher, V; Cento, V; Bernassola, M; Neumann-Fraune, M; Hemert, F; Chen, M; Salpini, R; Liu, C; Longo, R; Visca, M; Romano, S; Micheli, V; Bertoli, A; Gori, C; Ceccherini-Silberstein, F; Sarrecchia, C; Andreoni, M; Angelico, M; Ursitti, A; Spanò, A; Zhang, J; Verheyen, J; Cappiello, G; Perno, C";s:9:"metadata7";s:31:"10.1016/j.antiviral.2011.10.022";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:40;a:14:{s:9:"citazione";s:315:"Sarrecchia, C., Svicher, V., Volpi, A., Salpini, R., Ceccarelli, L., Sordillo, P., et al. (2011). Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. INFECTION [10.1007/s15010-011-0127-3].";s:4:"data";s:10:"2011-06-15";s:2:"id";s:19:"PUBBLICAZIONE_58916";s:6:"handle";s:10:"2108/18073";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:177:"Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance";s:9:"metadata6";s:111:"Sarrecchia, C; Svicher, V; Volpi, A; Salpini, R; Ceccarelli, L; Sordillo, P; Bertoli, A; Perno, CF; Andreoni, M";s:9:"metadata7";s:25:"10.1007/s15010-011-0127-3";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:41;a:14:{s:9:"citazione";s:214:"Ciccozzi, M., Babakir-Mina, M., Cella, E., Bertoli, A., Lo Presti, A., Maniar, J., et al. (2011). A case of Italian HIV-2 infection: a genetic analysis. AIDS RESEARCH AND HUMAN RETROVIRUSES [10.1089/AID.2011.0055].";s:4:"data";s:10:"2011-03-31";s:2:"id";s:19:"PUBBLICAZIONE_35809";s:6:"handle";s:10:"2108/18799";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:53:"A case of Italian HIV-2 infection: a genetic analysis";s:9:"metadata6";s:96:"Ciccozzi, M; Babakir-Mina, M; Cella, E; Bertoli, A; Lo Presti, A; Maniar, J; Perno, C; Ciotti, M";s:9:"metadata7";s:21:"10.1089/AID.2011.0055";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:42;a:14:{s:9:"citazione";s:344:"Alteri, C., Artese, A., Zang, J.M., Mercurio, F., Costa, G., Stazi, F., et al. (2011). Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia.";s:4:"data";s:4:"2011";s:2:"id";s:19:"PUBBLICAZIONE_87151";s:6:"handle";s:10:"2108/51958";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:162:"Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus";s:9:"metadata6";s:183:"Alteri, C; Artese, A; Zang, JM; Mercurio, F; Costa, G; Stazi, F; Fabeni, L; Bertoli, A; Forbici, F; Salpini, R; Dimonte, S; Alcaro, S; Ceccherini-Silberstein, F; Perno, CF; Svicher, V";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:43;a:14:{s:9:"citazione";s:315:"Cento, V., Mirabelli, C., Salpini, R., Han, Y., Mercurio, F., Dimonte, S., et al. (2011). Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution. Paper presented at 46th Annual meeting of the European Association for the study of the liver, Berlin, Germany.";s:4:"data";s:4:"2011";s:2:"id";s:19:"PUBBLICAZIONE_86814";s:6:"handle";s:10:"2108/51932";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:112:"Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution";s:9:"metadata6";s:332:"Cento, V; Mirabelli, C; Salpini, R; Han, Y; Mercurio, F; Dimonte, S; Beggel, B; Wittkop, L; Fraune, M; Gori, C; Bertoli, A; Micheli, V; Guberino, G; Longo, R; Romano, S; Visca, M; Gallinaro, V; Marino, M; Mazzotta, F; De Sanctis, GM; Tremulet, P; Angelico, M; Zhang, XX; Verheyen, J; Ceccherini-Silberstein, F; Perno, CF; Svicher, V";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:44;a:14:{s:9:"citazione";s:282:"Salpini, R., Svicher, V., Cento, V., Gori, C., Bertoli, A., Scopelliti, F., et al. (2011). Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. ANTIVIRAL RESEARCH, 92(2), 382-385 [10.1016/j.antiviral.2011.08.013].";s:4:"data";s:4:"2011";s:2:"id";s:20:"PUBBLICAZIONE_208349";s:6:"handle";s:10:"2108/99312";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:35:"Settore MED/17 - Malattie Infettive";s:9:"metadata4";N;s:9:"metadata5";s:121:"Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.";s:9:"metadata6";s:175:"Salpini, R; Svicher, V; Cento, V; Gori, C; Bertoli, A; Scopelliti, F; Micheli, V; Cappiello, T; Spanò, A; Rizzardini, G; De Sanctis, GM; Sarrecchia, C; Angelico, M; Perno, CF";s:9:"metadata7";s:31:"10.1016/j.antiviral.2011.08.013";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:45;a:14:{s:9:"citazione";s:269:"Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2011). The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia.";s:4:"data";s:4:"2011";s:2:"id";s:19:"PUBBLICAZIONE_87569";s:6:"handle";s:10:"2108/52061";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:85:"The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion";s:9:"metadata6";s:185:"Santoro, M; Armenia, D; Fabeni, L; Santoro, M; Gori, C; Forbici, F; Cento, V; Svicher, V; Bertoli, A; Dori, L; Andreoni, M; Narciso, P; Antinori, A; CECCHERINI SILBERSTEIN, F; Perno, Cf";s:9:"metadata7";s:25:"10.1007/s15010-011-0090-z";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:46;a:14:{s:9:"citazione";s:316:"Sarrecchia, C., Svicher, V., Volpi, A., Salpini, R., Ceccarelli, L., Sordillo, P., et al. (2011). Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. INFECTION [10.1007/s15010-011-0127-3.].";s:4:"data";s:4:"2011";s:2:"id";s:20:"PUBBLICAZIONE_208350";s:6:"handle";s:10:"2108/99313";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:35:"Settore MED/17 - Malattie Infettive";s:9:"metadata4";N;s:9:"metadata5";s:178:"Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.";s:9:"metadata6";s:111:"Sarrecchia, C; Svicher, V; Volpi, A; Salpini, R; Ceccarelli, L; Sordillo, P; Bertoli, A; Perno, CF; Andreoni, M";s:9:"metadata7";s:26:"10.1007/s15010-011-0127-3.";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:47;a:14:{s:9:"citazione";s:331:"Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Chen, M., Salpini, R., et al. (2011). Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection. Paper presented at International Workshop on HIV & Hepatitis virus Drug Resistance and curative strategies, Los Cabos (Mexico).";s:4:"data";s:4:"2011";s:2:"id";s:19:"PUBBLICAZIONE_86590";s:6:"handle";s:10:"2108/51895";s:9:"metadata1";s:21:"Intervento a convegno";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:104:"Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection";s:9:"metadata6";s:317:"Svicher, V; Cento, V; Bernassola, M; Neumann-Fraune, M; Chen, M; Salpini, R; Chang, L; Longo, R; Visca, M; Romano, S; Micheli, V; Bertoli, A; Gubertini, G; Marino, N; Mazzotta, F; Sarrecchia, C; Andreoni, M; Angelico, M; Ursitti, A; Spanò, A; Ceccherini Silberstein, F; Zhan, JM; Verheyen, J; Cappiello, G; Perno, CF";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:48;a:14:{s:9:"citazione";s:255:"Svicher, V., Cento, V., Salpini, R., Mercurio, F., Fraune, M., Beggel, B., et al. (2011). Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. DIGESTIVE AND LIVER DISEASE, 43(12), 975-983 [10.1016/j.dld.2011.07.002].";s:4:"data";s:4:"2011";s:2:"id";s:19:"PUBBLICAZIONE_62703";s:6:"handle";s:10:"2108/18062";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:90:"Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development";s:9:"metadata6";s:333:"Svicher, V; Cento, V; Salpini, R; Mercurio, F; Fraune, M; Beggel, B; Han, Y; Gori, C; Wittkop, L; Bertoli, A; Micheli, V; Gubertini, G; Longo, R; Romano, S; Visca, M; Gallinaro, V; Marino, N; Mazzotta, F; De Sanctis, GM; Fleury, H; Trimoulet, P; Angelico, M; Cappiello, G; Zhang, XX; Verheyen, J; Ceccherini-Silberstein, F; Perno, CF";s:9:"metadata7";s:25:"10.1016/j.dld.2011.07.002";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:49;a:14:{s:9:"citazione";s:263:"Svicher, V., Alteri, C., Gori, C., Salpini, R., Marcuccilli, F., Bertoli, A., et al. (2010). Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. DIGESTIVE AND LIVER DISEASE, 42(12), 902-907 [10.1016/j.dld.2010.04.017].";s:4:"data";s:7:"2010-12";s:2:"id";s:19:"PUBBLICAZIONE_35847";s:6:"handle";s:10:"2108/18495";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:95:"Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia";s:9:"metadata6";s:294:"Svicher, V; Alteri, C; Gori, C; Salpini, R; Marcuccilli, F; Bertoli, A; Longo, R; Bernassola, M; Gallinaro, V; Romano, S; Visca, M; Ursitti, A; Feasi, M; Micheli, V; Angelico, M; Cassola, G; Parruti, G; Gubertini, G; De Sanctis, GM; Ceccherini-Silberstein, F; Cappiello, G; Spanò, A; Perno, CF";s:9:"metadata7";s:25:"10.1016/j.dld.2010.04.017";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:50;a:14:{s:9:"citazione";s:299:"Svicher, V., D'Arrigo, R., Alteri, C., Andreoni, M., Angarano, G., Antinori, A., et al. (2010). Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. NEW MICROBIOLOGICA, 33(3), 195-206.";s:4:"data";s:7:"2010-07";s:2:"id";s:19:"PUBBLICAZIONE_35813";s:6:"handle";s:10:"2108/39772";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:166:"Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group";s:9:"metadata6";s:721:"Svicher, V; D'Arrigo, R; Alteri, C; Andreoni, M; Angarano, G; Antinori, A; Antonelli, G; Bagnarelli, P; Baldanti, F; Bertoli, A; Borderi, M; Boeri, E; Bonn, I; Bruzzone, B; Callegaro, AP; Cammarota, R; Canducci, F; Ceccherini-Silberstein, F; Clementi, M; Monforte, AD; De Luca, A; Di Biagio, A; Di Gianbenedetto, S; Di Perri, G; Di Pietro, M; Fabeni, L; Fadda, G; Galli, M; Gennari, W; Ghisetti, V; Giacometti, A; Gori, A; Leoncini, F; Maggiolo, F; Maserati, R; Mazzotta, F; Micheli, V; Meini, G; Monno, L; Mussini, C; Nozza, S; Paolucci, S; Parisi, S; Pecorari, M; Pizzi, D; Quirino, T; Re, MC; Rizzardini, G; Santangelo, R; Soria, A; Stazi, F; Sterrantino, G; Turriziani, O; Viscoli, C; Vullo, V; Lazzarin, A; Perno, CF";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:51;a:14:{s:9:"citazione";s:331:"Santoro, M., Bertoli, A., Lorenzini, P., Ceccherini-Silberstein, F., Gianotti, N., Mussini, C., et al. (2009). Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients. INFECTION, 37(3), 233-243 [10.1007/s15010-008-8065-4].";s:4:"data";s:7:"2009-06";s:2:"id";s:19:"PUBBLICAZIONE_81714";s:6:"handle";s:10:"2108/47515";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:164:"Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients";s:9:"metadata6";s:218:"Santoro, M; Bertoli, A; Lorenzini, P; Ceccherini-Silberstein, F; Gianotti, N; Mussini, C; Torti, C; Di Perri, G; Barbarini, G; Bini, T; Melzi, S; Caramello, P; Maserati, R; Narciso, P; Micheli, V; Antinori, A; Perno, C";s:9:"metadata7";s:25:"10.1007/s15010-008-8065-4";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:52;a:14:{s:9:"citazione";s:335:"Tozzi, V., Bellagamba, R., Castiglione, F., Amendola, A., Ivanovic, J., Nicastri, E., et al. (2008). Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART. AIDS RESEARCH AND HUMAN RETROVIRUSES, 24(6), 787-796 [10.1089/aid.2007.0236].";s:4:"data";s:7:"2008-06";s:2:"id";s:19:"PUBBLICAZIONE_82378";s:6:"handle";s:10:"2108/26955";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:155:"Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART";s:9:"metadata6";s:227:"Tozzi, V; Bellagamba, R; Castiglione, F; Amendola, A; Ivanovic, J; Nicastri, E; Libertone, R; D'Offizi, G; Liuzzi, G; Gori, C; Forbici, F; D'Arrigo, R; Bertoli, A; Salvatori, M; Capobianchi, M; Antinori, A; Perno, C; Narciso, P";s:9:"metadata7";s:21:"10.1089/aid.2007.0236";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:53;a:14:{s:9:"citazione";s:295:"Santoro, M., Bertoli, A., Lorenzini, P., Lazzarin, A., Esposito, R., Carosi, G., et al. (2008). Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS PATIENT CARE AND STDS, 22(1), 7-16 [10.1089/apc.2007.0013].";s:4:"data";s:7:"2008-01";s:2:"id";s:19:"PUBBLICAZIONE_82355";s:6:"handle";s:10:"2108/28934";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:133:"Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study";s:9:"metadata6";s:197:"Santoro, M; Bertoli, A; Lorenzini, P; Lazzarin, A; Esposito, R; Carosi, G; Di Perri, G; Filice, G; Moroni, M; Rizzardini, G; Caramello, P; Maserati, R; Narciso, P; Cargnel, A; Antinori, A; Perno, C";s:9:"metadata7";s:21:"10.1089/apc.2007.0013";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:54;a:14:{s:9:"citazione";s:359:"Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M., Forbici, F., et al. (2007). Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. JOURNAL OF VIROLOGY, 81(20), 11507-11519 [10.1128/JVI.00303-07].";s:4:"data";s:7:"2007-10";s:2:"id";s:19:"PUBBLICAZIONE_81713";s:6:"handle";s:10:"2108/45988";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:189:"Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors";s:9:"metadata6";s:190:"Ceccherini-Silberstein, F; Svicher, V; Sing, T; Artese, A; Santoro, M; Forbici, F; Bertoli, A; Alcaro, S; Palamara, G; d'Arminio Monforte, A; Balzarini, J; Antinori, A; Lengauer, T; Perno, C";s:9:"metadata7";s:20:"10.1128/JVI.00303-07";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:55;a:14:{s:9:"citazione";s:227:"Zaccarelli, M., Tozzi, V., Lorenzini, P., Forbici, F., Narciso, P., Ceccherini-Silberstein, F., et al. (2007). The V118I mutation as a marker of advanced HIV infection and disease progression. ANTIVIRAL THERAPY, 12(2), 163-168.";s:4:"data";s:4:"2007";s:2:"id";s:19:"PUBBLICAZIONE_81712";s:6:"handle";s:10:"2108/45989";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:80:"The V118I mutation as a marker of advanced HIV infection and disease progression";s:9:"metadata6";s:167:"Zaccarelli, M; Tozzi, V; Lorenzini, P; Forbici, F; Narciso, P; Ceccherini-Silberstein, F; Trotta, M; Bertoli, A; Liuzzi, G; Marconi, P; Mosti, S; Perno, C; Antinori, A";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:56;a:14:{s:9:"citazione";s:301:"Nadembega, W., Giannella, S., Simpore, J., Ceccherini-Silberstein, F., Pietra, V., Bertoli, A., et al. (2006). Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. JOURNAL OF MEDICAL VIROLOGY, 78(11), 1385-1391 [10.1002/jmv.20709].";s:4:"data";s:7:"2006-11";s:2:"id";s:19:"PUBBLICAZIONE_81711";s:6:"handle";s:10:"2108/43633";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:121:"Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso";s:9:"metadata6";s:186:"Nadembega, W; Giannella, S; Simpore, J; Ceccherini-Silberstein, F; Pietra, V; Bertoli, A; Pignatelli, S; Bellocchi, M; Nikiema, J; Cappelli, G; Bere, A; Colizzi, V; Perno, C; Musumeci, S";s:9:"metadata7";s:17:"10.1002/jmv.20709";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:57;a:14:{s:9:"citazione";s:308:"Aquaro, S., D'Arrigo, R., Svicher, V., Perri, G., Caputo, S., Visco-Comandini, U., et al. (2006). Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 58(4), 714-722 [10.1093/jac/dkl306].";s:4:"data";s:7:"2006-10";s:2:"id";s:19:"PUBBLICAZIONE_82377";s:6:"handle";s:10:"2108/26959";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:133:"Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment";s:9:"metadata6";s:198:"Aquaro, S; D'Arrigo, R; Svicher, V; Perri, G; Caputo, S; Visco-Comandini, U; Santoro, M; Bertoli, A; Mazzotta, F; Bonora, S; Tozzi, V; Bellagamba, R; Zaccarelli, M; Narciso, P; Antinori, A; Perno, C";s:9:"metadata7";s:18:"10.1093/jac/dkl306";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:58;a:14:{s:9:"citazione";s:311:"Svicher, V., Sing, T., Santoro, M., Forbici, F., Rodríguez-Barrios, F., Bertoli, A., et al. (2006). Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. JOURNAL OF VIROLOGY, 80(14), 7186-7198 [10.1128/JVI.02084-05].";s:4:"data";s:7:"2006-07";s:2:"id";s:19:"PUBBLICAZIONE_81726";s:6:"handle";s:10:"2108/43573";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:145:"Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors";s:9:"metadata6";s:205:"Svicher, V; Sing, T; Santoro, M; Forbici, F; Rodríguez-Barrios, F; Bertoli, A; Beerenwinkel, N; Bellocchi, M; Gago, F; d'Arminio Monforte, A; Antinori, A; Lengauer, T; Ceccherini-Silberstein, F; Perno, C";s:9:"metadata7";s:20:"10.1128/JVI.02084-05";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:59;a:14:{s:9:"citazione";s:279:"Santoro, M., Svicher, V., Gori, C., Zaccarelli, M., Tozzi, V., Forbici, F., et al. (2006). Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. NEW MICROBIOLOGICA, 29(2), 89-100.";s:4:"data";s:7:"2006-04";s:2:"id";s:19:"PUBBLICAZIONE_81724";s:6:"handle";s:10:"2108/43574";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:152:"Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy";s:9:"metadata6";s:210:"Santoro, M; Svicher, V; Gori, C; Zaccarelli, M; Tozzi, V; Forbici, F; D'Arrigo, R; Trotta, M; Bellocchi, M; Visco-Comandini, U; Cenci, A; Bertoli, A; Narciso, P; Antinori, A; Perno, C; Ceccherini-Silberstein, F";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:60;a:14:{s:9:"citazione";s:267:"Tozzi, V., Zaccarelli, M., Bonfigli, S., Lorenzini, P., Liuzzi, G., Trotta, M., et al. (2006). Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. ANTIVIRAL THERAPY, 11(5), 553-560.";s:4:"data";s:4:"2006";s:2:"id";s:19:"PUBBLICAZIONE_82381";s:6:"handle";s:10:"2108/26922";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:136:"Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome";s:9:"metadata6";s:155:"Tozzi, V; Zaccarelli, M; Bonfigli, S; Lorenzini, P; Liuzzi, G; Trotta, M; Forbici, F; Gori, C; Bertoli, A; Bellagamba, R; Narciso, P; Perno, C; Antinori, A";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:61;a:14:{s:9:"citazione";s:348:"Ceccherini-Silberstein, F., Gago, F., Santoro, M., Gori, C., Svicher, V., Rodríguez-Barrios, F., et al. (2005). High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. JOURNAL OF VIROLOGY, 79(16), 10718-10729 [10.1128/JVI.79.16.10718-10729.2005].";s:4:"data";s:7:"2005-08";s:2:"id";s:19:"PUBBLICAZIONE_82024";s:6:"handle";s:10:"2108/42284";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:154:"High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations";s:9:"metadata6";s:189:"Ceccherini-Silberstein, F; Gago, F; Santoro, M; Gori, C; Svicher, V; Rodríguez-Barrios, F; d'Arrigo, R; Ciccozzi, M; Bertoli, A; d'Arminio Monforte, A; Balzarini, J; Antinori, A; Perno, C";s:9:"metadata7";s:34:"10.1128/JVI.79.16.10718-10729.2005";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:62;a:14:{s:9:"citazione";s:251:"Bertoli, A., Franco, M., Balzarini, J., Johansson, M., & Karlsson, A. (2005). Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster. THE FEBS JOURNAL, 272(15), 3918-3928.";s:4:"data";s:10:"2005-06-19";s:2:"id";s:20:"PUBBLICAZIONE_247532";s:6:"handle";s:11:"2108/128017";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";s:1317:"The multisubstrate nucleoside kinase of Drosophila melanogaster (Dm-dNK) can be expressed in human solid tumor cells and its unique enzymatic properties makes this enzyme a suicide gene candidate. In the present study, Dm-dNK was stably expressed in the CCRF-CEM and H9 T-lymphoblastoid cell lines. The expressed enzyme was localized to the cell nucleus and the enzyme retained its activity. The Dm-dNK overexpressing cells showed approximately 200-fold increased sensitivity to the cytostatic activity of several nucleoside analogs, such as the pyrimidine nucleoside analogs (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and 1-beta-d-arabinofuranosylthymine (araT), but not to the antiherpetic purine nucleoside analogs ganciclovir, acyclovir and penciclovir, which may allow this technology to be applied in donor T cells and/or rescue graft vs. host disease to permit modulation of alloreactivity after transplantation. The most pronounced effect on the steady-state dNTP levels was a two- to 10-fold increased dTTP pool in Dm-dNK expressing cells that were grown in the presence of 1 microm of each natural deoxyribonucleoside. Although the Dm-dNK expressing cells demonstrated dNTP pool imbalances, no mitochondrial DNA deletions or altered mitochondrial DNA levels were detected in the H9 Dm-dNK expressing cells.";s:9:"metadata5";s:134:"Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster";s:9:"metadata6";s:62:"Bertoli, A; Franco, M; Balzarini, J; Johansson, M; Karlsson, A";s:9:"metadata7";s:32:"10.1111/j.1742-4658.2005.04808.x";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:63;a:14:{s:9:"citazione";s:337:"Perno, C., Cozzi-Lepri, A., Forbici, F., Bertoli, A., Violin, M., Stella Mura, M., et al. (2004). Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. THE JOURNAL OF INFECTIOUS DISEASES, 189(11), 1983-1987 [10.1086/386307].";s:4:"data";s:10:"2004-06-01";s:2:"id";s:19:"PUBBLICAZIONE_80275";s:6:"handle";s:10:"2108/40662";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:165:"Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed";s:9:"metadata6";s:159:"Perno, C; Cozzi-Lepri, A; Forbici, F; Bertoli, A; Violin, M; Stella Mura, M; Cadeo, G; Orani, A; Chirianni, A; De Stefano, C; Balotta, C; d'Arminio Monforte, A";s:9:"metadata7";s:14:"10.1086/386307";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:64;a:14:{s:9:"citazione";s:236:"Santoro, M., Ceccherini-Silberstein, F., Gori, C., Svicher, V., Forbici, F., Bellocchi, M., et al. (2004). Temporal change in the use of genotypic resistance testing over the years 1999--2003. NEW MICROBIOLOGICA, 27(2 Suppl 1), 141-144.";s:4:"data";s:7:"2004-04";s:2:"id";s:19:"PUBBLICAZIONE_82014";s:6:"handle";s:10:"2108/40984";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:84:"Temporal change in the use of genotypic resistance testing over the years 1999--2003";s:9:"metadata6";s:170:"Santoro, M; Ceccherini-Silberstein, F; Gori, C; Svicher, V; Forbici, F; Bellocchi, M; d'Arrigo, R; Bertoli, A; Giannella, S; Trotta, M; Bonfigli, S; Antinori, A; Perno, C";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:65;a:14:{s:9:"citazione";s:292:"Violin, M., Cozzi-Lepri, A., Velleca, R., Vincenti, A., D'Elia, S., Chiodo, F., et al. (2004). Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS, 18(2), 227-235 [10.1097/00002030-200401230-00012].";s:4:"data";s:10:"2004-01-23";s:2:"id";s:19:"PUBBLICAZIONE_80274";s:6:"handle";s:10:"2108/40671";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:54:"Settore MED/07 - Microbiologia e Microbiologia Clinica";s:9:"metadata4";N;s:9:"metadata5";s:139:"Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy";s:9:"metadata6";s:153:"Violin, M; Cozzi-Lepri, A; Velleca, R; Vincenti, A; D'Elia, S; Chiodo, F; Ghinelli, F; Bertoli, A; d'Arminio Monforte, A; Perno, C; Moroni, M; Balotta, C";s:9:"metadata7";s:32:"10.1097/00002030-200401230-00012";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:66;a:14:{s:9:"citazione";s:276:"Ceccherini-Silberstein, F., Erba, F., Gago, F., Bertoli, A., Forbici, F., Bellocchi, M., et al. (2004). Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS, 18(12), 11-19 [10.1097/01.aids.0000131394.76221.02].";s:4:"data";s:4:"2004";s:2:"id";s:19:"PUBBLICAZIONE_16650";s:6:"handle";s:10:"2108/34520";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";N;s:9:"metadata3";s:14:"Settore BIO/10";s:9:"metadata4";N;s:9:"metadata5";s:112:"Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure";s:9:"metadata6";s:162:"Ceccherini-Silberstein, F; Erba, F; Gago, F; Bertoli, A; Forbici, F; Bellocchi, M; Gori, C; D'Arrigo, R; Marcon, L; Balotta, C; Antinori, A; Monforte, A; Perno, C";s:9:"metadata7";s:35:"10.1097/01.aids.0000131394.76221.02";s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}i:67;a:14:{s:9:"citazione";s:276:"MOLLACE, V., Salvemini, D., Riley, D., Muscoli, C., Iannone, M., Granato, T., et al. (2002). The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. JOURNAL OF LEUKOCYTE BIOLOGY, 71(1), 65-72.";s:4:"data";s:7:"2002-01";s:2:"id";s:20:"PUBBLICAZIONE_246422";s:6:"handle";s:11:"2108/133238";s:9:"metadata1";s:19:"Articolo su rivista";s:9:"metadata2";s:128:"Apoptosis; Astrocytes; Cells, Cultured; Culture Media, Conditioned; HIV Infections; Humans; Macrophages; Oxidative Stress; HIV-1";s:9:"metadata3";s:14:"Settore BIO/14";s:9:"metadata4";s:1078:"Apoptosis of neurons and astrocytes has been found in patients undergoing AIDS dementia complex. We demonstrated that supernatants from human primary macrophages (M/M) infected by HIV-1 lead human astroglial cells to oxidative stress, as shown by elevated levels of malondialdehyde, and then to apoptosis. Electron microscopy of astrocytes shortly incubated with HIV-1-infected M/M supernatants showed apoptotic blebbing, cytoplasmic loss, and chromatin condensation. Apoptosis was antagonized by pretreating astrocytes with the nonpeptidic superoxide dismutase (SOD) mimetic M40401 but not with anti-HIV-1 compounds, thus showing that apoptosis of astrocytes driven by HIV-1-infected M/M supernatants is mainly mediated by abnormal production of superoxide anions without relationship to HIV-1 replication in such cells. Overall results support the role of oxidative stress mediated by HIV-1-infected M/M as one of the leading causes of neurodegeneration in patients with HIV-1 and suggest the use of nonpeptidic SOD mimetics to counteract HIV-1-related neurological disorders.";s:9:"metadata5";s:138:"The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages";s:9:"metadata6";s:156:"MOLLACE, V; Salvemini, D; Riley, D; Muscoli, C; Iannone, M; Granato, T; Masuelli, L; MODESTI, A; Rotiroti, D; NISTICO', RG; BERTOLI, A; PERNO, CF; AQUARO, S";s:9:"metadata7";N;s:9:"metadata8";N;s:9:"metadata9";N;s:10:"metadata10";N;}}" } ["meta_keywords"]=> array(1) { [0]=> string(1) "," } ["reserved"]=> array(1) { [0]=> string(1) "0" } ["auth_ip"]=> array(1) { [0]=> string(1) "0" } } ["_fieldBoosts":protected]=> array(6) { ["content_id"]=> bool(false) ["content_title"]=> bool(false) ["description"]=> bool(false) ["meta_keywords"]=> bool(false) ["reserved"]=> bool(false) ["auth_ip"]=> bool(false) } } }